Search Results
Your search for 3 matches 15112 pages
Showing 2351 - 2400Risk-Reducing Medication in Patients With High-Risk, ER-Positive Breast Cancer: Benefits and Harms
In a study reported in the Journal of Clinical Oncology, Jayasekera et al identified the benefits and harms of using risk-reducing medication in addition to screening in patients with high-risk, estrogen receptor (ER)-positive breast cancer. As stated by the investigators, “Recent studies,...
KEYNOTE-394: Pembrolizumab as Second-Line Therapy in Asian Patients With Advanced HCC
As reported in the Journal of Clinical Oncology by Qin et al, the phase III KEYNOTE-394 trial showed overall and progression-free survival benefits with pembrolizumab vs placebo in previously treated Asian patients with advanced hepatocellular carcinoma (HCC). Study Details The double-blind trial...
Addition of Adjuvant Nab-paclitaxel to Gemcitabine in Pancreatic Ductal Adenocarcinoma
As reported in the Journal of Clinical Oncology by Margaret A. Tempero, MD, and colleagues, the phase III APACT trial has shown no improvement in independently assessed disease-free survival (the study’s primary endpoint) with the addition of adjuvant nab-paclitaxel to gemcitabine in...
Mitomycin Gel for Upper Tract Urothelial Cancers: Postmarket Analysis
Researchers have performed the first postmarkert analysis of a novel delivery system of mitomycin—a gel formation, also known as UGN-101—to treat upper tract urothelial cancers, according to a novel study published by Woldu et al in Urologic Oncology. Their findings showcase how the treatment is...
EMERALD Trial: Elacestrant vs Standard Endocrine Monotherapy for Advanced Breast Cancer After CDK4/6 Inhibition
Elacestrant—an investigational oral selective estrogen receptor degrader (SERD)—achieved longer progression-free survival vs standard-of-care endocrine monotherapy as second- or third-line therapy in patients with estrogen receptor–positive, HER2-negative advanced or metastatic breast cancer in the ...
Phase III IMerge Trial of Imetelstat in Lower-Risk MDS
Positive results were announced from the phase III IMerge trial (ClinicalTrials.gov identifier NCT02598661) evaluating the first-in-class telomerase inhibitor imetelstat in patients with lower-risk myelodysplastic syndromes (MDS) who are relapsed, refractory, or ineligible for...
Crizotinib Combined With Chemotherapy in Pediatric ALK-Positive Anaplastic Large Cell Lymphoma
As reported in the Journal of Clinical Oncology by Lowe et al, findings in an arm of the Children’s Oncology Group phase II ANHL12P1 trial (arm CZ) showed high event-free and overall survival rates with the addition of crizotinib to chemotherapy in newly diagnosed pediatric patients with...
Late Mortality, Subsequent Malignant Neoplasms, and Chronic Health Conditions Among Survivors of Neuroblastoma Diagnosed During Infancy
In an analysis from the Childhood Cancer Survivor Study reported in the Journal of Clinical Oncology, Friedman et al found low rates of late mortality and subsequent malignant neoplasms in survivors of neuroblastoma treated in infancy. The risk of severe chronic health conditions decreased during...
World Cancer Day 2023: February 4
World Cancer Day 2023 is now only 1 month away! Led by the Union for International Cancer Control (UICC) and organized annually on February 4, World Cancer Day is a global initiative to improve awareness and knowledge of cancer risks and better prevent, detect, and treat the disease. World Cancer...
Updated Data From a Phase II Trial of Triplet Therapy in HPV-Positive Cancers
Expanded interim data from a phase II clinical trial investigating PDS0101-based triple combination therapy in advanced human papillomavirus (HPV)-positive cancers were recently announced. The triple combination of PDS0101—a novel T-cell HPV-specific immunotherapy—with the tumor-targeting IL-12...
Adjuvant Endocrine Therapy and Ovarian Suppression for Premenopausal Patients With Hormone Receptor–Positive Breast Cancer: 12-Year Results of the SOFT Trial
As reported in the Journal of Clinical Oncology by Prudence A. Francis, MD, and colleagues, 12-year results of the phase III SOFT trial show a maintained disease-free survival benefit with the addition of ovarian function suppression to adjuvant tamoxifen in premenopausal patients with hormone...
Risk Prediction Model for Contralateral Breast Cancer in BRCA Carriers With Breast Cancer
In a Chinese study reported in the Journal of Clinical Oncology, Sun et al developed a risk prediction model (BRCA-CRisk) to assess the risk of contralateral breast cancer in patients with breast cancer and BRCA1/2 pathogenic/likely pathogenic variants. Study Details The model was developed in a...
One in Seven Diagnosed Cancers Is Found by Recommended Screening Tests
Despite widespread awareness of the importance of screening for asymptomatic, early detection of cancer, screening tests exist for only five cancer types. With few recommended cancer screening tests and generally low adherence to cancer screening recommendations, it is difficult to detect cancer...
Hypofractionated 3-Week Course of Preoperative Radiotherapy for Soft-Tissue Sarcomas
In a single-center phase II trial (HYPORT-STS) reported in The Lancet Oncology, Guadagnolo et al found that a hypofractionated 3-week course of preoperative radiotherapy was safe in patients with soft-tissue sarcomas and may serve as an alternative to conventionally fractionated radiotherapy in...
Silicone Film to Prevent Acute Radiation Dermatitis in Patients With Breast Cancer
In a Canadian phase III trial reported in the Journal of Clinical Oncology, Behroozian et al found that the use of Mepitel film—a silicone-based polyurethane film dressing—significantly reduced the incidence of grade 2 or 3 acute radiation dermatitis vs usual care in at-risk women receiving...
FDA Approves Mosunetuzumab-axgb, a First-in-Class Bispecific Antibody, in Relapsed or Refractory Follicular Lymphoma
On December 22, the U.S. Food and Drug Administration (FDA) approved mosunetuzumab-axgb (Lunsumio) for the treatment of adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. Mosunetuzumab-axgb is a CD20/CD3 T-cell–engaging bispecific antibody and...
Sotorasib Shows Clinically Meaningful Activity Among Patients With KRAS G12C–Mutated Advanced Pancreatic Cancer
The KRAS G12C inhibitor sotorasib demonstrated clinically meaningful anticancer activity with an acceptable safety profile in heavily pretreated patients with KRAS G12C–mutated metastatic pancreatic cancer, accordi�ng to a novel study published by Strickler et al in The New England Journal of...
Mirvetuximab Soravtansine for FRɑ-Positive, Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
On November 14, 2022, the U.S. Food and Drug Administration (FDA) granted mirvetuximab soravtansine-gynx accelerated approval for patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three...
Concomitant and Sequential Nivolumab, Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma
As reported in the Journal of Clinical Oncology by Bröckelmann et al, final results of the German Hodgkin Study Group phase II NIVAHL trial indicate nearly 100% progression-free survival and 100% overall survival at 3 years among patients with early-stage unfavorable classical Hodgkin lymphoma...
A Lifelong Love of Science Leads to a Leadership Role in Oncology for Laurie Glimcher, MD
For this installment of The ASCO Post’s Living a Full Life series, Guest Editor Jame Abraham, MD, FACP, spoke with Laurie Glimcher, MD, President and Chief Executive Officer (CEO) of Dana-Farber Cancer Institute (DFCI). She is also Director of the Dana-Farber/Harvard Cancer Center, Principal...
Chronic Myelomonocytic Leukemia: Treatment and Prognosis, Part 2
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In the concluding half of this two-part installment, which began in our November 25 issue, Drs. Syed Ali Abutalib and Mrinal M. Patnaik continue to explore the current...
Expert Point of View: Joelle Fathi, DNP, RN, ARNP, CTTS, FAAN
An expert on the panel discussion of lung cancer screening from the Quantitative Imaging Workshop XIX, Joelle Fathi, DNP, RN, ARNP, CTTS, FAAN, Chief Healthcare Delivery Officer for the GO2 Foundation for Lung Cancer, called the lung cancer screening study a powerful reminder of the reality on the...
Managing Severe Diarrhea in Patients With Cancer
Diarrhea in patients with cancer is a well-known phenomenon with clear guidelines for prevention and management. However, it remains a condition with poorly explored consequences and a lack of sufficient and fast-acting treatments. In a webinar presented by members of the Multinational Association...
How ASCO and the Oncology Community Came Together to Discuss Progress in Global Cancer Control and the Challenges Ahead
After a 4-year in-person hiatus because of the COVID-19 global pandemic, the World Cancer Congress, hosted by the Union for International Cancer Control (UICC), held its first hybrid in-person and virtual meeting in October in Geneva. The conference brought together more than 2,000 attendees from...
Changing Landscape in the Management of High-Risk Lesions for Breast Cancer
As the population of women at increased risk for breast cancer grows, with an estimated 140,000 high-risk lesions diagnosed each year, “the landscape for surgical excision of high-risk lesions continues to evolve,” Melissa Pilewskie, MD, reported at the 2022 Lynn Sage Breast Cancer Symposium in...
Risk-Reducing Bilateral Mastectomy May Help Women With High-Penetrance Genetic Mutations to Avoid Cancer
“Risk-reducing bilateral mastectomy allows a woman with a high-penetrance breast cancer-causing mutation to avoid an encounter with the experience of breast cancer diagnosis and treatment,” Seema A. Khan, MD, MPH, stated at the 2022 Lynn Sage Breast Cancer Symposium.1 For these women, by avoiding...
Expert Point of View: Rimas V. Lukas, MD
Rimas V. Lukas, MD, a neuro-oncologist at Northwestern Medicine Lou and Jean Malnati Brain Tumor Institute, Chicago, praised the investigators’ willingness to explore relatively new areas of cancer research. “This is an interesting study by a strong group delving further into the nervous...
From the Clinic to the Lab: Overcoming Resistance to Immune Checkpoint Therapy
As a result of breakthroughs in immune checkpoint inhibitors over the past decade, immunotherapy has joined surgery, radiation therapy, and chemotherapy as one of the pillars of cancer treatment. However, nearly half of patients still do not benefit from immune checkpoint blockade. During the 2022...
Study Finds Lifileucel Active in Advanced Melanoma After Disease Progression on Immune Checkpoint Inhibitors
Cell therapy with tumor-infiltrating lymphocytes (TIL) may address an important unmet need for patients with difficult-to-treat melanoma after disease progression on immune checkpoint inhibitors, according to data presented during the 2022 Society for Immunotherapy of Cancer (SITC) Annual ...
T-DXd Confirmed as Preferred Second-Line Therapy for Metastatic HER2-Positive Breast Cancer
The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) proved to be superior to the antibody-drug conjugate ado-trastuzumab emtansine (T-DM1), significantly improving progression-free survival and overall survival, in women with unresectable or metastatic HER2-positive breast cancer as ...
How Telemedicine Can Transform Clinical Research and Practice
The COVID-19 pandemic transformed the world, and nowhere more so than in the health-care arena. Significant changes happened almost overnight in the delivery of medical care to focus on the safety and convenience of patients, staff, and providers. Although pilot efforts to integrate telemedicine...
How the American Cancer Society Aims to Improve Outcomes in Breast and Cervical Cancers and Reduce Health Disparities
Just days before the publication of the 2022 Annual Report to the Nation on the Status of Cancer on October 27, 2022,1 which showed a continued downward trend in cancer deaths, Karen Knudsen, MBA, PhD, Chief Executive Officer of the American Cancer Society (ACS), joined the First Lady Dr. Jill...
Ribociclib Plus Endocrine Therapy vs Combination Chemotherapy for Patients With Breast Cancer: Focus on Those in Visceral Crisis
According to findings from the phase II RIGHT Choice trial, many premenopausal patients with metastatic hormone receptor–positive, HER2-negative breast cancer experiencing visceral crisis are best treated with first-line ribociclib plus endocrine therapy rather than with chemotherapy.1 Ribociclib,...
In Stage IV NSCLC, Anti-TIGIT Antibody Boosts Immunotherapy Benefit
In the phase II ARC-7 study, when domvanalimab, a novel antibody that blocks T-cell immunoglobulin and ITIM domain (TIGIT), was added to immunotherapy for patients with stage IV non–small cell lung cancer (NSCLC), the combination resulted in improved response rates and progression-free survival...
Cardiovascular Events Before and After Initiation of Immune Checkpoint Inhibitor Therapy for Cancer: Agreement Between ICD-Coded and -Adjudicated Events
In a study reported in JACC: CardioOncology, Kondapalli et al found that cardiovascular events common in the general population were observed both prior to and after initiation of immune checkpoint inhibitor therapy for cancer; myocarditis was more common posttreatment, but infrequent. Agreement...
Nivolumab Plus Cabozantinib With or Without Ipilimumab in Advanced Hepatocellular Carcinoma
As reported in the Journal of Clinical Oncology by Thomas Yau, MD, and colleagues, findings in a cohort of the phase I/II CheckMate 040 trial indicated the activity of nivolumab/cabozantinib with or without ipilimumab in patients with advanced hepatocellular carcinoma. Study Details In the...
Sodium Thiosulfate to Reduce the Risk of Cisplatin-Related Ototoxicity in Pediatric Patients With Localized Solid Tumors
On September 20, 2022, sodium thiosulfate was approved to reduce the risk of ototoxicity associated with cisplatin in pediatric patients (aged ≥ 1 month) with localized, nonmetastatic solid tumors.1 Supporting Efficacy Data Approval was based on findings in the multicenter open-label SIOPEL 6...
Ivosidenib/Azacitidine for Newly Diagnosed IDH1-Mutant Acute Myeloid Leukemia in Patients Aged 75 or Older or With Comorbidities
On May 25, 2022, ivosidenib was approved for use in combination with azacitidine for newly diagnosed acute myeloid leukemia with a susceptible IDH1 mutation, as detected by a U.S. Food and Drug Administration–approved test, in patients aged 75 or older or in those who have comorbidities precluding...
Interim Analysis of Overall Survival in the monarchE Trial
As reported in The Lancet Oncology by Stephen R.D. Johnston, MD, PhD, and colleagues, an interim analysis of overall survival in the phase III monarchE trial has shown no significant benefit with the addition of adjuvant abemaciclib to endocrine therapy in patients with hormone receptor–positive,...
Traditional Chinese Medicine Herbal Formula Shen Ling Bai Zhu San for Chronic Diarrhea
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Yen Nien (Jason) Hou, PharmD, DiplOM, LAc, and Jyothirmai Gubili, MS, focus on ...
Robin Zon, MD, FACP, FASCO, Elected ASCO President for 2024–2025 Term
ASCO has elected Robin Zon, MD, FACP, FASCO, a long-time member and volunteer, to lead as its President beginning in June 2024. Dr. Zon will take office as President-Elect immediately following the ASCO Annual Business Meeting in Chicago on June 5, 2023. Five additional members were also elected to ...
From Immigrant Roots to a Budding Career in Oncology, Gladys Magaly Rodriguez, MD, Aims to Advance Health Equity in Vulnerable Populations
Gladys Magaly Rodriguez, MD, was born in Piedras Negras, Mexico, a city situated along the banks of the Rio Grande. At age 6, her family immigrated to Eagle Pass, Texas, a border town of some 30,000 people that is predominantly Latinx and Spanish speaking. “Even though I lived and attended school...
Tremelimumab Combined With Durvalumab and Platinum-Based Chemotherapy in Metastatic NSCLC
On November 10, 2022, tremelimu-mab in combination with durvalumab and platinum-based chemotherapy was approved for patients with metastatic non–small cell lung cancer (NSCLC) with no sensitizing EGFR mutation or ALK genomic tumor aberrations.1 Supporting Efficacy Data Approval was supported by...
Alex Herrera, MD, Finds a Path From the Baseball Fields of Miami to a Leadership Role at City of Hope
Lymphoma expert Alex Herrera, MD, was born in Miami; his parents were just 19 years old when he was born. Dr. Herrera’s father was born in Puerto Rico to Cuban and Ecuadorian parents. His mother was born in Cuba and came to the United States via Operation Peter Pan, the clandestine program that...
Understanding the Health Provisions in the Inflation Reduction Act and Their Implications for Oncology Care
The Inflation Reduction Act of 2022, signed into law on August 16, 2022, contains several important provisions regarding health care and drug pricing.1 In this article, I provide an overview of the legislation’s implications for oncology care, focusing on its provisions concerning drug price...
Prostate Cancer Screening With MRI-Targeted vs MRI-Targeted and Systemic Biopsy
In a Swedish study (GÖTEBORG-2) reported in The New England Journal of Medicine, Hugosson et al found that magnetic resonance imaging (MRI)-targeted prostate biopsy was associated with a lower risk of overdiagnosis of clinically insignificant prostate cancer compared with MRI-targeted and...
Indiana University Names Music Therapy Researcher Sheri Robb, PhD, as New Walther Professor of Supportive Oncology
Indiana University (IU) School of Medicine has named Sheri Robb, PhD, a Walther Professor of Supportive Oncology. This is one of five endowed positions to develop a supportive oncology program that encompasses research and patient care. Dr. Robb is a nationally renowned music therapy researcher,...
Brentuximab Vedotin Combined With Chemotherapy in Pediatric Classical Hodgkin Lymphoma
On November 10, 2022, brentuximab vedotin was approved for use in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide for pediatric patients aged ≥ 2 years with previously untreated high-risk classical Hodgkin lymphoma.1 Supporting Efficacy Data Approval was...
First-Line Nivolumab/Ipilimumab vs EXTREME Regimen in Recurrent or Metastatic Head and Neck Cancer
The final results of the phase III CheckMate 651 trial showed no significant overall survival benefit with first-line nivolumab/ipilimumab vs the EXTREME regimen (cetuximab plus cisplatin or carboplatin plus fluorouracil for up to six cycles, followed by cetuximab maintenance) in recurrent or...
FDA Approves First Gene Therapy for High-Risk Non–Muscle-Invasive Bladder Cancer
On December 16, the U.S. Food and Drug Administration (FDA) approved nadofaragene firadenovec-vncg (Adstiladrin), a nonreplicating adenoviral vector–based gene therapy indicated for the treatment of adult patients with high-risk bacillus Calmette-Guérin (BCG)-unresponsive non–muscle-invasive...
